中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝细胞癌的临床诊治:从指南到临床实践

王涛 陈东风

王涛,陈东风. 肝细胞癌的临床诊治:从指南到临床实践[J]. 临床肝胆病杂志, 2021, 37(8): 1745-1747. DOI: 10.3969/j.issn.1001-5256.2021.08.001
引用本文: 王涛,陈东风. 肝细胞癌的临床诊治:从指南到临床实践[J]. 临床肝胆病杂志, 2021, 37(8): 1745-1747. DOI: 10.3969/j.issn.1001-5256.2021.08.001
WANG T, CHEN DF. Clinical diagnosis and treatment of hepatocellular carcinoma: From guidelines to clinical practice[J]. J Clin Hepatol, 2021, 37(8): 1745-1747. DOI: 10.3969/j.issn.1001-5256.2021.08.001
Citation: WANG T, CHEN DF. Clinical diagnosis and treatment of hepatocellular carcinoma: From guidelines to clinical practice[J]. J Clin Hepatol, 2021, 37(8): 1745-1747. DOI: 10.3969/j.issn.1001-5256.2021.08.001

肝细胞癌的临床诊治:从指南到临床实践

DOI: 10.3969/j.issn.1001-5256.2021.08.001
基金项目: 

国家自然科学基金青年科学基金项目 82002585

重庆市自然科学基金面上项目 cstc2020jcyj-msxmX0171

详细信息
    通讯作者:

    陈东风,chendf1981@126.com

  • 中图分类号: R735.7

Clinical diagnosis and treatment of hepatocellular carcinoma: From guidelines to clinical practice

Funds: 

National Natural Science Foundation of China Young Scientist Fund 82002585

General Project of Chongqing Natural Science Foundation cstc2020jcyj-msxmX0171

  • 摘要: 肝细胞癌(HCC)发病隐匿,进展速度快,治疗效果差,是严重危害人民健康的常见恶性肿瘤。因此,国内外众多学术研究团体针对HCC筛查、诊断、治疗等方面的关键问题,发布了基于循证医学证据的多项肝癌诊治指南并不断进行更新。临床医生需在结合自身专业背景的基础上,对指南进行全面学习,以提高对肝癌领域相关进展的认识,进一步提高HCC患者的治疗效果。

     

  • [1] CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/caac.21338.
    [2] GORDAN JD, KENNEDY EB, ABOU-ALFA GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline[J]. J Clin Oncol, 2020, 38(36): 4317-4345. DOI: 10.1200/JCO.20.02672.
    [3] Bureau of Medical AdministrationNational Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.

    中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
    [4] ZHOU J, YU L, GAO X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma[J]. J Clin Oncol, 2011, 29(36): 4781-4788. DOI: 10.1200/JCO.2011.38.2697.
    [5] SUN YF, XU Y, YANG XR, et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection[J]. Hepatology, 2013, 57(4): 1458-1468. DOI: 10.1002/hep.26151.
    [6] QU C, WANG Y, WANG P, et al. Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy[J]. Proc Natl Acad Sci U S A, 2019, 116(13): 6308-6312. DOI: 10.1073/pnas.1819799116.
    [7] Guidelines Working Committee of Chinese Society of Clinical Oncology. Guidelines for the diagnosis and treatment of primary liver cancer (2020 edition)[M]. Beijing: People's Medical Publishing House, 2020.

    中国临床肿瘤学会指南工作委员会. 原发性肝癌诊疗指南2020[M]. 北京: 人民卫生出版社, 2020.
    [8] BI F, QIN S, GU S, et al. Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicentre phase Ⅱ/Ⅲ trial[C]. Chicago, 2020 ASCO Annual Meeting Symposium: abstract 4506.
    [9] YUAN GS, HE WM, HU XY, et al. Clinical efficacy and safety analysis of camrelizumab combined with apatinib as a second-line therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study[J]. Chin J Hepatol, 2021, 29(4): 326-331. DOI: 10.3760/cma.j.cn501113-20210329-00148.

    袁国盛, 何伟猛, 胡晓云, 等. 卡瑞利珠单克隆抗体联合阿帕替尼二线治疗不可切除肝细胞癌的临床疗效及安全性分析: 一项多中心回顾性研究[J]. 中华肝脏病杂志, 2021, 29(4): 326-331. DOI: 10.3760/cma.j.cn501113-20210329-00148.
    [10] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. DOI: 10.1016/j.jhep.2018.03.019.
    [11] CALLEJA JL, CRESPO J, RINCÓN D, et al. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort[J]. J Hepatol, 2017, 66(6): 1138-1148. DOI: 10.1016/j.jhep.2017.01.028.
    [12] MARRERO JA, KULIK LM, SIRLIN CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 68(2): 723-750. DOI: 10.1002/hep.29913.
    [13] TANG A, BASHIR MR, CORWIN MT, et al. Evidence supporting LI-RADS major features for CT-and MR imaging-based diagnosis of hepatocellular carcinoma: A systematic review[J]. Radiology, 2018, 286(1): 29-48. DOI: 10.1148/radiol.2017170554.
  • 加载中
计量
  • 文章访问数:  234
  • HTML全文浏览量:  55
  • PDF下载量:  157
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-05-28
  • 修回日期:  2021-05-28
  • 刊出日期:  2021-08-16
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回